Polymorphisms of pro-inflammatory genes and prostate cancer risk: A pharmacogenomic approach

Cancer Immunology, Immunotherapy

Volumn 58, Issue 12, 2009, Pages 1919-1933

  Caruso, Calogero ^a,b,c   Balistreri, Carmela Rita ^a   Candore, Giuseppina ^a   Carruba, Giuseppe ^a   Colonna Romano, Giuseppina ^a   Di Bona, Danilo ^a,b,d   Forte, Giusi Irma ^a   Lio, Domenico ^a   Listì, Florinda ^a   Scola, Letizia ^a,b   Vasto, Sonya ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b Medicina Trasfusionale ed Immunoematologia   (Italy)

^c ARNAS Ospedale Civico   (Italy)

^d CNR   (Italy)

Author keywords

Aging; Genetics; Inflammation; Longevity; Pharmacogenomics; Prostate cancer

Indexed keywords

AUTACOID;

AGING; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; MALE; PHARMACOGENETICS; PROSTATE TUMOR; REVIEW;

AGING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS;

EID: 79958117754     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0658-y     Document Type: Conference Paper

References (159)

1. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK (2003) Cancer survival and incidence from the surveillance, epidemiology, and end results (SEER) program. Oncologist 8:541-552 (Pubitemid 37467370)
2. Serrano M, Blasco MA (2007) Cancer and ageing: convergent and divergent mechanisms. Nat Rev Mol Cell Biol 8:715-722 (Pubitemid 47312829)
3. Finkel T, Serrano M, Blasco MA (2007) The common biology of cancer and ageing. Nature 448:767-774 (Pubitemid 47266334)
4. Vasto S, Carruba G, Lio D, Colonna-Romano G, Di Bona D, Candore G, Caruso C (2008) Inflammation, ageing, and cancer. Mech Ageing Dev. (Epub ahead of print)
5. Derhovanessian E, Solana R, Larbi A, Pawelec G (2008) Immunity, ageing and cancer. Immun Ageing 5:11
6. Finn OJ (2006) Human tumor antigens, immunosurveillance, and cancer vaccines. Immunol Res 36:73-82
7. Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90:1-50 (Pubitemid 43765795)
8. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860-867 (Pubitemid 36019639)
9. Hussain T, Gupta S, Mukhta H (2003) Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191:125-135 (Pubitemid 36255597)
10. Shacter E, Weitzman SA (2002) Chronic inflammation and cancer. Oncology (Williston Park) 16:217-226
11. Hsu PI, Lai KH, Hsu PN, Lo GH, Yu HC, Chen WC, Tsay FW, Lin HC, Tseng HH, Ger LP, Chen HC (2007) Helicobacter pylori infection and the risk of gastric malignancy. Am J Gastroenterol 102(4):102725-102730
12. Zisman TL, Rubin DT (2008) Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol 714:266-269
13. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252-266 (Pubitemid 34196319)
14. Caruso C, Lio D, Cavallone L, Franceschi C (2004) Aging, longevity, inflammation, and cancer. Ann N Y Acad Sci 1028:1-13 (Pubitemid 40361805)
15. Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A (2008) Pathways connecting inflammation and cancer. Curr Opin Genet Dev 1:3-10 (Pubitemid 351694444)
16. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436-444
17. Borrello MG, Alberti L, Fischer A, Degl'innocenti D, Ferrario C, Gariboldi M, Marchesi F, Allavena P, Greco A, Collini P, Pilotti S, Cassinelli G, Bressan P, Fugazzola L, Mantovani A, Pierotti MA (2005) Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 102:14825-14830 (Pubitemid 41457140)
18. De Marzo AM, Coffey DS, Nelson WG (1999) New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology 53:29-39
19. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics. CA Cancer J Clin 57:43-66
20. IARC http://www.dep.iarc.fr/
21. Vasto S, Carruba G, Candore G, Italiano E, Di Bona D, Caruso C (2008) Inflammation and prostate cancer. Future Oncol 4:637-645
22. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB (2004) The role of inflammation in the pathogenesis of prostate cancer. J Urol 172:S6-S11
23. Hochreiter WW, Nadler RB, Koch AE, Campbell PL, Ludwig M, Weidner W, Schaeffer AJ (2000) Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. Urology 56:1025-1029
24. Fujita K, Ewing CM, Sokoll LJ, Elliott DJ, Cunningham M, De Marzo AM, Isaacs WB, Pavlovich CP (2008) Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. Prostate 68:872-882 (Pubitemid 351845218)
25. Franks LM (1954) Atrophy and hyperplasia in the prostate proper. J Pathol Bacteriol 68:617-621
26. Bennett BD, Richardson PH, Gardner WA (1993) Histopathology and cytology of prostatitis. In: Lepor H, Lawson RK (eds) Prostate disease. Saunders, Philadelphia, pp 399-414
27. De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, Nelson WG (2003) Human prostate cancer precursors and pathobiology. Urology 62:55-62 (Pubitemid 37371890)
28. Putzi MJ, De Marzo AM (2000) Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 56:828-832
29. Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA (2001) Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am J Pathol 158:1767-1773 (Pubitemid 32422941)
30. De Marzo AM, Marchi VL, Epstein JI, Nelson WG (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155:1985-1992
31. Dennis LK, Lynch CF, Torner JC (2002) Epidemiologic association between prostatitis and prostate cancer. Urology 60:78-83 (Pubitemid 34722951)
32. Roberts RO, Bergstralh EJ, Bass SE, Lieber MM, Jacobsen SJ (2004) Prostatitis as a risk factor for prostate cancer. Epidemiology 15:93-99 (Pubitemid 40417002)
33. Montironi R, Mazzucchelli R, Scarpelli M (2002) Precancerous lesions and conditions of the prostate: from morphological and biological characterization to chemoprevention. Ann NY Acad Sci 963:169-184 (Pubitemid 34721709)
34. Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL (2005) Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol 173(6):1969-1974 (Pubitemid 40675222)
35. Hayes RB, Pottern LM, Strickler H, Rabkin C, Pope V, Swanson GM, Greenberg RS, Schoenberg JB, Liff J, Schwartz AG, Hoover RN, Fraumeni JF Jr (2000) Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer 82:718-725 (Pubitemid 30085213)
36. Strickler HD, Goedert J (2001) Sexual behaviour and evidence for an infectious cause of prostate cancer. Epidemiol Rev 23:144-151 (Pubitemid 32906627)
37. Dennis LK, Dawson DV (2002) Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13:72-79 (Pubitemid 34031513)
38. Taylor ML, Mainous AG, Wells BJ (2005) Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 37:506-512 (Pubitemid 40967713)
39. Rosenblatt KA, Wicklund KG, Stanford JL (2001) Sexual factors and the risk of prostate cancer. Am J Epidemiol 153:1152-1158 (Pubitemid 32552272)
40. Carruba G (2007) Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem 102:899-911
41. Bosland MC, Ford H, Horton L (1995) Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17β or diethylstilbestrol. Carcinogenesis 16:1311-1317
42. Candore G, Lio D, Colonna Romano G, Caruso C (2002) Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions. Autoimmun Rev 1:29-35 (Pubitemid 38372146)
43. Tam NN, Leav I, Ho SM (2007) Sex hormones induce direct epithelial and inflammation-mediated oxidative/nitrosative stress that favors prostatic carcinogenesis in the noble rat. Am J Pathol 171:1334-1341 (Pubitemid 47582906)
44. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7:256-269 (Pubitemid 46486616)
45. Harris MT, Feldberg RS, Lau KM, Lazarus NH, Cochrane DE (2000) Expression of proinflammatory genes during estrogen-induced inflammation of the rat prostate. Prostate 44:19-25 (Pubitemid 30390061)
46. Risbridger GP, Bianco JJ, Ellem SJ, McPherson SJ (2003) Oestrogens and prostate cancer. Endocr Relat Cancer 10:187-191 (Pubitemid 36758648)
47. Prins GS, Huang L, Birch L, Pu Y (2006) The role of estrogens in normal and abnormal development of the prostate gland. Ann N Y Acad Sci 1089:1-13 (Pubitemid 47092064)
48. Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP (2004) Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 89:2434-2441 (Pubitemid 38619887)
49. Bulun SE, Simpson ER (2008) Aromatase expression in women's cancers. Adv Exp Med Biol 630:112-312
50. Risbridger GP, Ellem SJ, McPherson SJ (2007) Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. J Mol Endocrinol 39:183-188 (Pubitemid 350047640)
51. Bianco JJ, McPherson SJ, Wang H, Prins GS, Risbridger GP (2006) Transient neonatal exposure to estrogen-deficient mice (Aromatase knockout) reduces prostate weight and induces inflammation in late life. Am J Pathol 168:1869-1878 (Pubitemid 43825307)
52. Onsory K, Sobti RC, Al-Badran AI, Watanabe M, Shiraishi T, Krishan A, Mohan H, Kaur P (2008) Hormone receptor-related gene polymorphisms and prostate cancer risk in north Indian population. Mol Cell Biochem 314:25-35
53. Cussenot O, Azzouzi AR, Nicolaiew N, Fromont G, Mangin P, Cormier L, Fournier G, Valeri A, Larre S, Thibault F, Giordanella JP, Pouchard M, Zheng Y, Hamdy FC, Cox A, Cancel-Tassin G (2007) Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J Clin Oncol 25:3596-3602 (Pubitemid 47376605)
54. Huang YC, Chen M, Lin MW, Chung MY, Chang YH, Huang WJ, Wu TT, Hsu JM, Yang S, Chen YM (2007) CYP19 TCT trinucleotide Del/Del genotype is a susceptibility marker for prostate cancer in a Taiwanese population. Urology 69:996-1000 (Pubitemid 46670253)
55. Tsuchiya N, Wang L, Suzuki H, Segawa T, Fukuda H, Narita S, Shimbo M, Kamoto T, Mitsumori K, Ichikawa T, Ogawa O, Nakamura A, Habuchi T (2006) Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 124:1982-1989 (Pubitemid 46622105)
56. Modugno F, Weissfeld JL, Trump DL, Zmuda JM, Shea P, Cauley JA, Ferrell RE (2001) Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 7:3092-3096 (Pubitemid 32963829)
57. Latil AG, Azzouzi R, Cancel GS, Guillaume EC, Cochan-Priollet B, Berthon PL, Cussenot O (2001) Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 192:1130-1137 (Pubitemid 32861661)
58. Stram DO, Haiman CA, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, Pike MC (2003) Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 55:27-36 (Pubitemid 36928743)
59. Suzuki K, Nakazato H, Matsui H, Koike H, Okugi H, Kashiwagi B, Nishii M, Ohtake N, Nakata S, Ito K, Yamanaka H (2003) Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol- O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer 198:1411-1416 (Pubitemid 37151495)
60. Fukatsu T, Hirokawa Y, Araki T, Hioki T, Murata T, Suzuki H, Ichikawa T, Tsukino H, Qiu D, Katoh T, Sugimura Y, Yatani R, Shiraishi T, Watanabe M (2004) Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res 24:2431-2437 (Pubitemid 39166328)
61. Mononen N, Seppälä EH, Duggal P, Autio V, Ikonen T, Ellonen P, Saharinen J, Saarela J, Vihinen M, Tammela TL, Kallioniemi O, Bailey-Wilson JE, Schleutker J (2006) Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res 66:743-747 (Pubitemid 43165937)
62. Li L, Cicek MS, Casey G, Witte JS (2004) No association between a tetranucleotide repeat polymorphism of CYP19 and prostate cancer. Cancer Epidemiol Biomarkers Prev 13:2280-2281 (Pubitemid 40054331)
63. Candore G, Balistreri CR, Grimaldi MP, Listì F, Vasto S, Chiappelli M, Licastro F, Colonna-Romano G, Lio D, Caruso C (2007) Polymorphisms of pro-inflammatory genes and Alzheimer's disease risk: a pharmacogenomic approach. Mech Ageing Dev 128:67-75 (Pubitemid 46073062)
64. Listì F, Caruso M, Incalcaterra E, Hoffmann E, Caimi G, Balistreri CT, Vasto S, Scafidi V, Caruso C, Candore G (2008) Pro-inflammatory gene variants in myocardial infarction and longevity: implications for pharmacogenomics. Curr Pharm Des 14:2678-2685
65. Vane JR, Bakhle YS, Botting RM (1998) Cyclooxigenase 1 and 2. Annu Rev Pharmacol Toxicol 38:97-120
66. Smith WL, Garavito RM, DeWitt DL (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271:33157-33160 (Pubitemid 27010118)
67. Taketo MM (1998) COX-2 and colon cancer. Inflamm Res 47:S112-S116
68. Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimito T, Namiki M, Mizokami A (2002) Cyclooxygenase-2 promotes prostate cancer progression. Prostate 53:232-240 (Pubitemid 35266184)
69. Edwards J, Mukherjee R, Munro AF, Wells AC, Almushatat A, Bartlett JM (2004) Her2 and COX2 expression in human prostate cancer. Eur J Cancer 40:50-55 (Pubitemid 37542317)
70. Aparicio Gallego G, Díaz Prado S, Jiménez Fonseca P, García Campelo R, Cassinello Espinosa J, Antón Aparicio LM (2007) Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer. Clin Transl Oncol 9:694-702
71. Wang W, Bergh A, Damber JE (2004) Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 61:60-72 (Pubitemid 39095695)
72. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE (1998) Cyclooxygenase in biology and disease. FASEB J 12:1063-1073 (Pubitemid 28418937)
73. Lin DW, Nelson PS (2003) The role of cyclooxygenase-2 inhibition for the prevention and treatment of prostate carcinoma. Clin Prostate Cancer 2:119-126 (Pubitemid 37296107)
74. Basler JW, Piazza GA (2004) Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 171:S59-S62
75. Subbaramaiah K, Dannenberg AJ (2003) Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24:96-102 (Pubitemid 36135884)
76. Singh A, Purohit A, Ghilchik MW, Reed MJ (1999) The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2. Endocr Relat Cancer 6:139-147 (Pubitemid 29260045)
77. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER (1996) Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137:5739-5742 (Pubitemid 26423150)
78. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM (1999) Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140:27-35 (Pubitemid 29251310)
79. Frasor J, Weaver AE, Pradhan M, Mehta K (2008) Synergistic upregulation of prostaglandin E synthase expression in breast cancer cells by 17b-estradiol and pro-inflammatory cytokines. Endocrinology 149(12):6272-6279
80. Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA (2001) Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther 299:468-476 (Pubitemid 32979657)
81. Panguluri RC, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F, Jackson A, Weinrich S, Ahaghotu C, Isaacs W, Kittles RA (2004) COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 25:961-966 (Pubitemid 38886082)
82. Shahedi K, Lindström S, Zheng SL, Wiklund F, Adolfsson J, Sun J, Augustsson-Bälter K, Chang BL, Adami HO, Liu W, Grönberg H, Xu J (2006) Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer 119:668-672 (Pubitemid 43955722)
83. Hedelin M, Chang ET, Wiklund F, Bellocco R, Klint A, Adolfsson J, Shahedi K, Xu J, Adami HO, Grönberg H, Bälter KA (2007) Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer 120:398-405 (Pubitemid 44956853)
84. Chen YQ, Duniec ZM, Liu B, Hagmann W, Gao X, Shimoji K, Marnett LJ, Johnson CR, Honn KV (1994) Endogenous 12(S)- HETE production by tumor cells and its role in metastasis. Cancer Res 54:1574-1579 (Pubitemid 24106425)
85. Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman CC, Kelloff GJ (1999) Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 8:467-483 (Pubitemid 29230553)
86. Ghosh J, Myers CE (1998) Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA 95:13182-13187 (Pubitemid 28509545)
87. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H (2001) Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 91:737-743 (Pubitemid 32173298)
88. Franceschi C, Motta L, Motta M, Malaguarnera M, Capri M, Vasto S, Candore G, Caruso C, IMUSCE (2008) The extreme longevity: the state of the art in Italy. Exp Gerontol 43:45-52
89. Miyake K (2007) Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 19:3-10
90. Uematsu S, Akira S (2008) Toll-like receptors (TLRs) and their ligands. Handb Exp Pharmacol 183:1-20
91. Tsan MF, Gao B (2004) Endogenous ligands of Toll-like receptors. J Leukoc Biol 76:514-519
92. Balistreri CR, Grimaldi MP, Chiappelli M, Licastro F, Castiglia L, Listì F, Vasto S, Lio D, Caruso C, Candore G (2008) Association between the polymorphisms of TLR4 and CD14 genes and Alzheimer's disease. Curr Pharm Des 14:2672-2677
93. Balistreri CR, Candore G, Colonna-Romano G, Lio D, Caruso M, Hoffmann E, Franceschi C, Caruso C (2004) Role of Toll-like receptor 4 in acute myocardial infarction and longevity. JAMA 292:2339-2340 (Pubitemid 39491917)
94. Kawai T, Akira S (2007) Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 13:460-469
95. Tsan MF (2006) Toll-like receptors, inflammation and cancer. Semin Cancer Biol 16:32-37
96. Chen R, Alvero AB, Silasi DA, Steffensen KD, Mor G (2008) Cancers take their toll: the function and regulation of Toll-like receptors in cancer cells. Oncogene 27:225-233
97. Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM (2007) Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 7:1271-1285 (Pubitemid 47126372)
98. Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749-759 (Pubitemid 41400849)
99. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, Xiong H (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65:5009-5014 (Pubitemid 40827306)
100. Huang B, Zhao J, Shen S, Li H, He KL, Shen GX, Mayer L, Unkeless J, Li D, Yuan Y, Zhang GM, Xiong H, Feng ZH (2007) Listeria monocytogenes promote tumor growth via tumor cell Toll-like receptor 2 signaling. Cancer Res 67:4346-4352 (Pubitemid 46815083)
101. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G (2006) TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66:3859-3868
102. Nelson WG, De Marzo AM, Isaacs WB (2003) Prostate cancer. N Engl J Med 349:366-381 (Pubitemid 36886244)
103. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285-296 (Pubitemid 39061110)
104. Zheng SL, Augustsson-Bälter K, Chang B, Hedelin M, Li L, Adami HO, Bensen J, Li G, Johnasson JE, Turner AR, Adams TS, Meyers DA, Isaacs WB, Xu J, Grönberg H (2004) Sequence variants of Toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res 64:2918-2922 (Pubitemid 38500633)
105. Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ (2005) Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 65:11771-11778 (Pubitemid 41821739)
106. Cheng I, Plummer SJ, Casey G, Witte JS (2007) Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 16:352-355 (Pubitemid 46383358)
107. Sun J, Wiklund F, Zheng SL, Chang B, Bälter K, Li L, Johansson JE, Li G, Adami HO, Liu W, Tolin A, Turner AR, Meyers DA, Isaacs WB, Xu J, Grönberg H (2005) Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 97:525-532 (Pubitemid 40590434)
108. Chen YC, Giovannucci E, Kraft P, Lazarus R, Hunter DJ (2007) Association between Toll-like receptor gene cluster (TLR6, TLR1, and TLR10) and prostate cancer. Cancer Epidemiol Biomarkers Prev 16:1982-1989 (Pubitemid 47621171)
109. Stevens VL, Hsing AW, Talbot JT, Zheng SL, Sun J, Chen J, Thun MJ, Xu J, Calle EE, Rodriguez C (2008) Genetic variation in the Toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int J Cancer. 123(11):2644-2650
110. Kramer G, Mitteregger D, Marberger M (2007) Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51:1202-1216 (Pubitemid 46436310)
111. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV (1985) Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 316:701-705 (Pubitemid 16239342)
112. Miyazono K, Suzuki H, Imamura T (2003) Regulation of TGFbeta signalling and its roles in progression of tumors. Cancer Sci 94:230-234 (Pubitemid 36575887)
113. Brattain MG, Howell G, Sun LZ, Willson JK (1994) Growth factor balance and tumor progression. Curr Opin Oncol 6:77-81 (Pubitemid 2048447)
114. Fynan TM, Reiss M (1993) Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog 4:493-540
115. Cambien F, Ricard S, Troesch A, Mallet C, Générénaz L, Evans A, Arveiler D, Luc G, Ruidavets JB, Poirier O (1996) Polymorphisms of the transforming growth factor beta 1 gene in relation to myocardial infarction and blood pressure. Hypertension 28:881-887
116. Randall LL, Hardy SJ (1989) Unity in function in the absence of consensus in sequence: role of leader peptides in export. Science 243:1156-1159 (Pubitemid 19081141)
117. Faria PC, Saba K, Freitas Neves A, Cordeiro ER, Marangoni K, Garcia Freitas D, Goulart LR (2007) Transforming growth factor- beta 1 gene polymorphisms and expression in the blood of prostate cancer patients. Cancer Invest 25:726-732 (Pubitemid 350223179)
118. Arend WP, Malyak M, Guthridge CJ, Gabay C (1998) Interleukin- 1 receptor antagonist: role in biology. Annu Rev Immunol 16:27-55 (Pubitemid 28183358)
119. Dinarello CA (1994) The interleukin-1 family: 10 years of discovery. FASEB J 8:1314-1325
120. Giri D, Ittmann M (2000) Interleukin-1β is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 157:249-255 (Pubitemid 30641741)
121. Castro P, Giri D, Lamb D, Ittmann M (2003) Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate 55:30-38 (Pubitemid 36397742)
122. Ricote M, García-Tuñón I, Bethencourt FR, Fraile B, Paniagua R, Royuela M (2004) Interleukin-1 (IL-1α and IL-1β) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 7:1388-1396 (Pubitemid 38366841)
123. Konwar R, Gara R, Singh M, Singh V, Chattopadhyay N, Bid HK (2008) Association of interleukin-4 and interleukin-1 receptor antagonist gene polymorphisms and risk of benign prostatic hyperplasia. Urology 71:868-872 (Pubitemid 351609102)
124. Cheng I, Krumroy LM, Plummer SJ, Casey G, Witte JS (2007) MIC1 and IL1RN genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 16:1309-1311 (Pubitemid 46984978)
125. Lindmark F, Zheng SL, Wiklund F, Bälter KA, Sun J, Chang B, Hedelin M, Clark J, Johansson JE, Meyers DA, Adami HO, Isaacs W, Grönberg H, Xu J (2005) Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk. Br J Cancer 93:493-497 (Pubitemid 43080026)
126. Liu Y, Lin N, Huang L, Xu Q, Pang G (2007) Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol 26:613-618 (Pubitemid 47263208)
127. Giedraitis V, He B, Huang WX, Hillert J (2001) Cloning and mutation analysis of IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 112:146-152
128. Sugiura T, Kawaguchi Y, Harigai M, Terajima-Ichida H, Kitamura Y, Furuya T, Ichikawa N, Kotake S, Tanaka M, Hara M, Kamatani N (2002) Association between adult-onset Still's disease and interleukin-18 gene polymorphisms. Genes Immun 3:394-399 (Pubitemid 41656537)
129. Moore BB, Arenberg DA, Stoy K, Morgan T, Addison CL, Morris SB, Glass M, Wilke C, Xue YY, Sitterding S, Kunkel SL, Burdick MD, Strieter RM (1999) Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 154:1503-1512 (Pubitemid 29226445)
130. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE (1991) Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 174:1209-1220
131. Stearns ME, Rhim J, Wang M (1999) Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 5:189-196 (Pubitemid 29045193)
132. Eder T, Mayer R, Langsenlehner U, Renner W, Krippl P, Wascher TC, Pummer K, Kapp KS (2007) Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: a population-based study. Eur J Cancer 43:472-475 (Pubitemid 46177585)
133. Faupel-Badger JM, Kidd LC, Albanes D, Virtamo J, Woodson K, Tangrea JA (2008) Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control 19:119-124
134. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA, Howell WM (2002) Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62:3369-3372 (Pubitemid 34651380)
135. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, Hsing A, Huang WY, Hayes RB (2006) Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 66:4525-4530
136. Yang HP, Woodson K, Taylor PR, Pietinen P, Albanes D, Virtamo J, Tangrea JA (2006) Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial. Eur J Cancer Prev 15:249-253 (Pubitemid 43791771)
137. Zabaleta J, Lin H-Y, Sierra RA, Hall CM, Clark PE, Sartor OA, Hu JJ, Ochoa AC (2008) Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis 29:573-578 (Pubitemid 351404874)
138. Vaday GG, Peehl DM, Kadam PA, Lawrence DM (2006) Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 66:124-134 (Pubitemid 43191234)
139. König JE, Senge T, Allhoff EP, König W (2004) Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 58:121-129
140. Balistreri CR, Carruba G, Calabrò M, Campisi I, Di Carlo D, Lio D, Colonna-Romano G, Candore G, Caruso C (2009) CCR5 proinflammatory allele in prostate cancer risk: a pilot study in patients and centenarians from Sicily. Ann NY Acad Sci (in press)
141. Damber JE, Aus G (2008) Prostate cancer. Lancet 371:1710-1721
142. Xu J, Lowey J, Wiklund F, Sun J, Lindmark F, Hsu F-C, Dimitrov L, Chang B, Turner AR, Liu W, Adami H-O, Suh E, Moore JH, Zheng SL, Isaacs WB, Trent JM, Groënberg H (2005) The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol Biomarkers Prev 14:2563-2568 (Pubitemid 41752716)
143. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, Brint E, Dunne A, Gray P, Harte MT, McMurray D, Smith DE, Sims JE, Bird TA, O'Neill LA (2001) Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 413:78-83 (Pubitemid 32843491)
144. Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T, Hoshino K, Takeuchi O, Kobayashi M, Fujita T, Takeda K, Akira S (2002) Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 420:324-329 (Pubitemid 35398188)
145. Miyaishi O, Ando F, Matsuzawa K, Kanawa R, Isobe K (2000) Cancer incidence in old age. Mech Ageing Dev 117:47-55 (Pubitemid 30665792)
146. Stanta G, Campagner L, Cavallieri F, Giarelli L (1997) Cancer of the oldest old: what we have learned from autopsy studies. Clin Geriatr Med 13:55-68 (Pubitemid 27084043)
147. Vasto S, Candore G, Balistreri CR, Caruso M, Colonna-Romano G, Grimaldi MP, Listi F, Nuzzo D, Lio D, Caruso C (2007) Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev 128:83-91 (Pubitemid 46073064)
148. Capri M, Salvioli S, Monti D, Caruso C, Candore G, Vasto S, Olivieri F, Marchegiani F, Sansoni P, Baggio G, Mari D, Passarino G, De Benedictis G, Franceschi C (2008) Human longevity within an evolutionary perspective: the peculiar paradigm of a post-reproductive genetics. Exp Gerontol 43:53-60
149. Di Bona D, Vasto S, Capurso C, Christiansen L, Deiana L, Franceschi C, Hurme M, Mocchegiani E, Rea M, Lio D, Candore G, Caruso C (2009) Effect of interleukin-6 polymorphisms on human longevity: a systematic review and meta-analysis. Ageing Res Rev 8:36-42
150. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70 (Pubitemid 30046295)
151. Imyanitov EN (2008) Use of elderly tumor-free subjects as a "supercontrol" for cancer epidemiological studies: pros and cons. Mech Ageing Dev 130:122-127
152. van Heemst D, Mooijaart SP, Beekman M, Schreuder J, de Craen AJ, Brandt BW, Slagboom PE, Westendorp RG, Long Life study group (2005) Variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol 40:11-15 (Pubitemid 40138741)
153. Sardana G, Dowell B, Diamandis EP (2008) Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 54(12):1951-1960 (Pubitemid 352774027)
154. Vasto S, Candore G, Duro G, Lio D, Grimaldi MP, Caruso C (2007)
155. Candore G, Balistreri CR, Caruso M, Grimaldi MP, Incalcaterra E, Listì F, Vasto S, Caruso C (2007) Pharmacogenomics: a tool to prevent and cure coronary heart disease. Curr Pharm Des 13:3726-3734
156. Sooriakumaran P, Kaba R (2005) The risks and benefits of cyclooxygenase- 2 inhibitors in prostate cancer: a review. Int J Surg 3:278-285 (Pubitemid 43129688)
157. Puppo F, Murdaca G, Ghio M, Indiveri F (2005) Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev 4:537-541 (Pubitemid 41415766)
158. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR (2003) A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 63:8360-8365 (Pubitemid 37549490)
159. Wang RF Y, Miyahara Y, Wang HY (2008) Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 27:181-189